Bladder Cancer
Conditions
Keywords
Diclofenac, BCG, BLADDER IRRIGATIONS
Brief summary
This study is designed to test the effectiveness of diclofenac suppositories in the prophylaxis of side effects caused by BCG bladder irrigations in bladder cancer patients.
Detailed description
This study is designed as a double blind placebo controlled randomized study to evaluate the effectiveness of diclofenac suppositories in the prevention of side effects of BCG bladder irrigation in bladder cancer patients. After signing an informed consent, the patients will be randomized to either receive an unmarked suppository of Diclofenac or a placebo suppository. The effectiveness of the drug will be tested weekly by quality of life questionnaires and bladder symptom questionnaire. Another questionnaire is designed to monitor the time in minutes that the BCG is retained in the bladder before the patients urinates.
Interventions
DRUGAbitren
SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
DRUGPlacebo
Placebo suppositories
Sponsors
Carmel Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Bladder urothelial carcinoma patients scheduled fo a set of 6 BCG bladder irrigations at the Carmel Medical Centre 2. Male and female 3. Age 20-80. 4. Patients capable of understanding reading and signing the informed consent form in Hebrew.
Exclusion criteria
1. Diclofenac hypersensitivity 2. Pregnancy, Lactation 3. Elevated creatinine at baseline (male \> 1.2 mg/% female 1.0 mg/%) 4. Peptic gastric or duodenal ulcer 5. Acute or chronic inflammation of the rectum/ anus (diarrhea, rectal bleeding) 6. Gross hematuria (which is per se a contraindication for BCG irrigation)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in weekly COOP Questionnaire 1 | The questionnaires will be completed every week for the quality of life of the passing week. The complete time frame of all questionnaires will be 7 weeks | The bladder irrigations are delivered as an ambulatory treatment once a week. The questionnaires will be completed every week for the quality of life of the passing week. |
| Change in weekly COOP Questionnaire 2 | The questionnaires will be completed every week for the quality of life of the passing week. The complete time frame of all questionnaires will be 7 weeks | The bladder irrigations are delivered as an ambulatory treatment once a week. The questionnaires will be completed every week for the quality of life of the passing week. |
| Change in weekly COOP Questionnaire 3 | The questionnaires will be completed every week for the quality of life of the passing week. The complete time frame of all questionnaires will be 7 weeks | The bladder irrigations are delivered as an ambulatory treatment once a week. The questionnaires will be completed every week for the quality of life of the passing week. |
| Change in weekly Bladder symptoms Questionnaire | The questionnaires will be completed every week for the bladder symptoms of the passing week. The complete time frame of all questionnaires will be 7 weeks | Bladder symptoms Questionnaire correlated to BCG treatment. The bladder irrigations are delivered as an ambulatory treatment once a week. The questionnaires will be completed every week for the bladder symptoms of the passing week. |
| Change in weekly time schedule questionnaire | every week for 6 weeks | A questionnaire designed to measure the time in minutes that the patient was able to retain the BCG in the bladder.This questionnaire will be completed every week for the same day of weekly irrigation. |
Outcome results
None listed